NCT06849713 - Zanubrutinib, Obinutuzumab, and Sonrotoclax in Previously Untreated Patients With CLL or SLL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

March 1, 2028

Study Completion Date

March 1, 2030

Conditions

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma (SLL)

Interventions

DRUG

Zanubrutinib

Bruton's Tyrosine Kinase (BTK) inhibitor

DRUG

Sonrotoclax

B-cell lymphoma 2 (BCL2) protein inhibitor

DRUG

Obinutuzumab

Anti-CD20 monoclonal antibody

Trial Locations (2)

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Massachusetts General Hospital, Boston